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Abstract
Background: The hydroxynaphthoquinones have been extensively investigated over the past 50 years for their
anti-malarial activity. One member of this class, atovaquone, is combined with proguanil in Malarone®, an important
drug for the treatment and prevention of malaria.
Methods: Anti-malarial activity was assessed in vitro for a series of 3-alkyl-2-hydroxy-1,4-naphthoquinones (N1-N5)
evaluating the parasitaemia after 48 hours of incubation. Potential cytotoxicity in HEK293T cells was assessed using
the MTT assay. Changes in mitochondrial membrane potential of Plasmodium were measured using the fluorescent
dye Mitrotracker Red CMXROS.
Results: Four compounds demonstrated IC50s in the mid-micromolar range, and the most active compound, N3,
had an IC50 of 443 nM. N3 disrupted mitochondrial membrane potential, and after 1 hour presented an IC50ΔΨmit of
16 μM. In an in vitro cytotoxicity assay using HEK 293T cells N3 demonstrated no cytotoxicity at concentrations up
to 16 μM.
Conclusions: N3 was a potent inhibitor of mitochondrial electron transport, had nanomolar activity against
cultured Plasmodium falciparum and showed minimal cytotoxicity. N3 may serve as a starting point for the design
of new hydroxynaphthoquinone anti-malarials.
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Background
Despite the worldwide effort to understand molecular and
cellular features of Plasmodium falciparum, the main
aetiological agent of human malaria, the disease is still
devastating. Parasite resistance to older anti-malarials
raises the need for the development of new drugs [1,2].
The anti-malarials currently used stem from six drug clas-
ses: aminoquinolines, arylaminoalcohols, artemisinins,
antifolates, antibiotics and inhibitors of the respiratory
chain [3,4]. The last class is the subject of this report.
The hydroxynaphthoquinones have been extensively in-
vestigated over the past 50 years for their anti-malarial activ-
ity [5]. Hydrolapachol was the first hydroxynaphthoquinone
discovered that possessed anti-malarial activity [6]. This dis-
covery, which emerged at a time of great interest in the
study of hydroxynaphthoquinone derivatives as potential
new anti-malarials, resulted in the synthesis of a large family
of different hydrolapachol analogs [7]. Work on the anti-
malarial properties of hydroxynaphthoquinones was revived
when chloroquine resistance emerged, and it was discovered
that atovaquone effectively inhibits plasmodial electron
transport at the ubiquinone (coenzyme Q, 2) site [8].
Atovaquone is a hydroxynaphthoquinone that is used in
combination with proguanil (Malarone®) for prophylaxis
and therapy of uncomplicated malaria [9]. Atovaquone has
excellent anti-malarial activity but exhibits poor pharma-
ceutical properties, such as low bioavailability and high
plasma protein binding [10]. To improve drug bioavailabil-
ity, several atovaquone analogs were prepared and changes
were made to the naphthoquinone moiety, especially the
alkyl side chain, because it is known that modifying this
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chain can alter drug activity [7] and counteract drug
resistance [11-13]. Recently, it was demonstrated that 2-
methyl-heptyl or 2-methyl-heptyl-trifluoromethyl 2-hydroxy-
1,4-naphthoquinones were highly effective against atova-
quone-resistant P. falciparum [14].
The aim of this work was to test the activity of a new
series of hydroxynaphthoquinones [15] against P. falcip-
arum. One of these compounds, N3, had an IC50 against
cultured P. falciparum in the nM range, disrupted mito-
chondrial membrane potential, and had low toxicity
against human cells suggesting potential as a lead com-
pound for the development of new anti-malarial agents.
Methods
Chemistry
The hydroxynaphthoquinones N1-5 were recently syn-
thesized using a new methodology [15].
In vitro culture of P. falciparum
3D7 strain parasites were cultured and synchronized as de-
scribed previously [16,17]. Briefly, parasites were routinely
maintained in A+ human erythrocytes (1-3% parasitaemia
and 2% haematocrit) in RPMI-1640 media supplemented
with 0.2% sodium bicarbonate, 50 mg/L hypoxanthine and
10% type A+ human serum in 92% N2, 5% CO2 and 3% O2.
Cell culture of HEK293T
HEK293T (human embryonic kidney) cells were cul-
tured in 75 cm2 vented tissue culture flasks at 37°C in a
humidified atmosphere containing 5% CO2 in Dulbecco’s
modified essential medium (Gibco BRL) supplemented
with 10% (v/v) foetal bovine serum, 100 U/ml penicillin/
and 100 μg/ml streptomycin.
Flow cytometry analysis
Infected erythrocytes at the ring stage were incubated with
different concentrations of the test compounds (N1-N5
0.005, 0.015, 0.045, 0.137, 0.411, 1.23, 3.70, 11.11, 33.33
and 100 μM and atovaquone 0.005, 0.015, 0.045, 0.137,
0.411, 1.23, 3.70, 11.11, 33.33 and 100 nM) for 48 hours;
fixed in 2% paraformaldehyde in phosphate-buffered sa-
line (PBS) for 24 hours; permeabilized with 0.1% Triton
X-100 and 20 μg/ml RNase; incubated for 30 minutes at
37°C; and stained with 1 nM Yoyo-1 (Molecular Probes).
Parasitaemia was determined from dot plots (side
scatter versus fluorescence) of 5x104 cells acquired on a
FACSCalibur flow cytometer using CELLQUEST software
(Becton Dickinson). Initial gating was carried out with un-
stained, uninfected erythrocytes to account for erythrocyte
autofluorescence and analysis performed using Flow Jo
7.6.5 (TreeStar Inc).
Changes in mitochondrial membrane potential (ΨΔmit)
Loss of parasite mitochondrial membrane potential
(ΨΔmit) was determined using 5 μM Mitrotracker Red
CMXROS as described previously [18]. Cultures were
incubated for 30 min at 37°C with the dye and then
for 1 h with 10-fold serial dilutions (0.001-100 μM) of
N3 and atovaquone. As a control, 5 μM cyanide m-
chlorophenylhydrazone (CCCP), a protonophore that
dissipate the membrane potential, was used. Results
were analysed by flow cytometry as described above.
Cytotoxicity assays
The toxicity of hydroxynaphthoquinone derivatives to-
ward HEK293T cells was evaluated with the 4,5-
dimethylthiazol- 2-yl-2,5- diphenyltetrazolium bromide
(MTT) cell proliferation assay [19]. Cells (1.0 × 105/well)
were seeded into 48 well plates and incubated in complete
medium (Dulbecco’s Modified Eagle Media, GIBCO, Life
Technologies; supplemented with 10% foetal bovine
serum, 100 μg/ml streptomycin and 100 U/ml penicillin)
for 24 h. Thereafter, medium was removed and replaced
with complete medium (450 μl/well); N3, atovaquone, and
solvent (for controls) were added (0.128, 0.64, 3.2, 16, 80
and 400 μM) and cultures were incubated for 48 hours.
Cells were then incubated with the MTT reagent for
3 hours, and absorbance was evaluated.
Statistical analyses
Analyses of parasitaemia were performed by a one-way
analysis of variance test followed by post hoc analysis
by the Dunnett’s Multiple Comparison Test using
GraphPad Prism software. IC50 values were produced
using sigmoid dose-response curves on GraphPad soft-
ware. At least three independent experiments were
performed for each assay.
Results
In vitro activity of new hydroxynaphthoquinones
The ability of compounds N1-N5 to disrupt the in vitro
growth of P. falciparum was tested. The naphthoquinones
showed activity against P. falciparum, with IC50s of 0.4-
89 μM (Figure 1 and Additional file 1: Figure S1). Only
N3 had an IC50 in the nM range (443 nM; Figure 2).
Cytotoxicity effects on cells HEK293T
Cytotoxic activity against HEK293T cells was assessed
with a tetrazolium-based colorimetric assay. No signifi-
cant cytotoxicity was observed at concentrations below
16 μM. For N3, the concentration leading to 50% cell
death (CC50) was 54.6 ± 0.23 μM (Figure 1). For
atovaquone the CC50 was 49 ± 0.45 μM.
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Effect of N3 on ΔΨmit
It was also verified the effects of compound N3 on P.
falciparum mitochondrial membrane potential (ΔΨmit).
Compound N3 showed an IC50ΔΨmit = 16 μM and
atovaquone an IC50ΔΨmit = 4.4 μM (Figure 3).
Discussion
In an attempt to identify improved anti-malarials, the anti-
parasitic activities of synthetic hydroxynaphthoquinones
using in vitro assays was evaluated. It was identified one
compound, N3, with nanomolar activity against P. falcip-
arum, confirmed activity against mitochondrial electron
transport, and showed limited cytotoxicity against human
cells.
The cytochrome bc1 complex catalyses transfer of elec-
trons to maintain the membrane potential of mitochondria,
and it is a validated target for anti-malarial drugs.
Atovaquone is the only hydroxynaphthoquinone and in-
hibitor of the bc1 complex currently used to treat malaria.
It is generally efficacious, but suffers from irregular ab-
sorption (improved with fatty food), limited drug resist-
ance, and high cost of production [8,9,20]. Work to
counteract atovaquone limitations has identified other
hydroxynaphthoquinones with anti-malarial activity [8].
One series contained an ester at the 3-hydroxy group of
atovaquone, with nanomolar anti-malarial activity; addition
of long side chains decreased activity [11]. A series of 26
compounds based on the structure of rhinacanthin, a
naphthoquinone with anticancer properties, was synthe-
sized [21]; two of these had nanomolar activity and
inhibited the cytochrome bc1 complex of P. falciparum.
Another four hydroxynaphthoquinones were synthesized in
an attempt to circumvent resistance to atovaquone, which
is mediated by mutations in the mitochondrial cytochrome
b gene [13]. The addition of a methyl radical on the
naphthoquinone ring provided excellent activity against
atovaquone-resistant strains of P. falciparum, with docu-
mentation of inhibition of the cytochrome bc1 complex
[13]. It was recently screened 36 new anti-malarial
Figure 1 Biological activity of hydroxynaphtoquinones. Structure and biological activity of compounds N1-N5.
Figure 2 Effect of new hydroxynaphthoquinones on P.
falciparum growth. a) Structure of N3. b) Dose response curve for
compound N3 incubated for 48 h. Error bars represent standard
error of the mean.
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phenylsulfanylmethyl naphthoquinones structurally related
to lapachol [22]. The compounds had moderate in vitro ac-
tivity against P. falciparum.
Comparing the structures of atovaquone, N3 and
BW58-C (an atovaquone precursor), these three struc-
tures are very similar in molecular volume, though N3
is much simpler to prepare and has no chiral centers
(Figure 4) and, therefore, it can serve as a starting
point for a new series of hydroxynaphthoquinone anti-
malarials. The results indicate that the cyclohexane
ring of atovaquone is not essential for antimalarial ac-
tivity, since its replacement by a CH2 group in N3 only
slightly decreased activity, and N3 was capable of
inhibiting mitochondrial activity efficiently (Figures 2
and 3). Considering BW58-C, this molecule showed
excellent results against murine malaria [23] and good
Figure 3 Proposed mechanism of action of N3. P. falciparum 3D7 was loaded with Mitotracker Red CMXROS and ΔΨMit measured after 1-hour
incubations at the indicated concentrations using flow cytometry. a) Effects of compounds (dashed lines) compared to untreated controls (solid lines):
CCCP 5 μM; N3 100 μM and Atovaquone 100 μM. b) Dose responses of different concentrations of solvent control, atovaquone and N3 in the inhibition of
ΔΨMit. (*) indicates a statistically significant difference from control values (P < 0.05), data were compared using one-way ANOVA and Dunnett’s post test.
Figure 4 Structure of BW58-C, N3 and atovaquone pointing the main chemistry differences of compounds. Circles in the figure represent
chiral centers.
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activity against respiration of mitochondria [24], but it
was rapidly metabolized and eliminated in humans
[25]. Interaction with cytochrome P450 enzymes and
other aspects of metabolism are important compo-
nents of drug design, and evaluation of the metabolism
of N3 is needed.
Screening of a library of 2-hydroxy-naphthoquinones
found compounds with alkyl side-chains that effectively
inhibited the yeast bc1 complex [26]. In the present study,
was evaluated 5 additional hydroxynaphthoquinones, and
demonstrated that one of these, N3, was a potent inhibitor
of mitochondrial electron transport, had nanomolar activity
against cultured P. falciparum, and showed minimal cyto-
toxicity. Optimization of N3 thus offers potential for new
candidate compounds to treat and prevent malaria.
Additional file
Additional file 1: Figure S1. Structures of other
hydroxynaphthoquinones and effects on P. falciparum growth. Different
concentrations of compounds were incubated for 48 h with P.
falciparum. Results are shown as a dose response curve for compound
N1, N2, N4 and N5 incubated for 48 h. Error bars represent standard error
of the mean.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DCS carried out the in vitro assays and drafted the manuscript. SBF and DRR
carried out the chemical synthesis and collaborated in the elaboration of the
manuscript. LNC and MN carried out the cytotoxicity test and collaborated in
the elaboration of the manuscript. MN carried out the Plasmodium culture
and collaborated in the elaboration of the manuscript. CRSG and VFF
conceived of the study, and participated in its design and coordination and
collaborated in the elaboration of the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
This work was supported by FAPESP (Fundação de Amparo a Pesquisa de
São Paulo) (07/52924-0), by Malaria Pronex, and by a INCT-INBqMed (Instituto
Nacional de Ciência e Tecnologia- Instituto Nacional de Ciência e Tecnologia
de Biotecnologia Estrutural e Química Medicinal em Doenças Infecciosa)
grant. C.R.S. Garcia and V. Ferreira are CNPQ (Conselho Nacional de Pesquisa)
fellows. D.S. received a CAPES (Coordenação de Aperfeiçoamento de Pessoal
de Nível Superior) Fellowship. D.R. da Rocha thanks FAPERJ (Fundação de
Amparo a Pesquisa do Rio De Janeiro) for their doctoral fellowship. LNC and
MM received a FAPESP Fellowship. Thanks are due to the CNPQ, CAPES and
FAPERJ for funding this work.
Author details
1Departamento de Fisiologia, Universidade de São Paulo, São Paulo
05508-900, Brazil. 2Departamento de Química Orgânica, Universidade Federal
Fluminense, Niterói 24020-141, Brazil. 3Departamento de Química Orgânica,
Universidade Federal do Rio de Janeiro, Macaé 27930-560, Brazil.
4Department of Medicine, University of California, San Francisco, CA 94143,
USA. 5Universidade de São Paulo, Instituto de Biociências, Rua do Matão,
travessa 14, n.321 Cidade Universitária, CEP 05508-900 São Paulo, SP, Brazil.
Received: 14 December 2012 Accepted: 12 June 2013
Published: 10 July 2013
References
1. Gazarini ML, Sigolo CA, Markus RP, Thomas AP, Garcia CR: Antimalarial
drugs disrupt ion homeostasis in malarial parasites. Mem Inst Oswaldo
Cruz 2007, 102:329–334.
2. Garcia CR, de Azevedo MF, Wunderlich G, Budu A, Young JA, Bannister L:
Plasmodium in the postgenomic era: new insights into the molecular cell
biology of malaria parasites. Int Rev Cell Mol Biol 2008, 266:85–156.
3. Schlitzer M: Malaria chemotherapeutics part I: History of antimalarial
drug development, currently used therapeutics, and drugs in clinical
development. Chem Med Chem 2007, 2:944–986.
4. WHO: World Malaria Report. Geneva: World Health Organization; 2010.
5. Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum
antiparasitic drug, collapses mitochondrial membrane potential in a
malarial parasite. J Biol Chem 1997, 272:3961–3966.
6. Hooker SC: Lomatiol. II. Its occurrence, constitution, relation to and
conversion into lapachol. Also a synthesis of lapachol. J Am Chem Soc
1936, 58:1181–1190.
7. Fieser LF, Berliner E, Bondhus FJ, Chang FC, Dauben WG, Ettlinger MG,
Fields GFM, Fieser M, Heidelberger C, Heymann H, Seligman AM, Vaughan
WR, Wilson AG, Wilson E, Wu M, Leffler MT, Hamlin KE, Hathaway RJ, Matson
EJ, Moore EE, Moore MB, Rapala RT, Zaugg HE: Naphthoquinone
antimalarials.4.5.6.7.8.9.10.11. synthesis. J Am Chem Soc 1948,
70:3174–3215.
8. Barton V, Fisher N, Biagini GA, Ward SA, O’Neill PM: Inhibiting Plasmodium
cytochrome bc1: a complex issue. Curr Opin Chem Biol 2010, 14:440–446.
9. Baggish AL, Hill DR: Antiparasitic agent atovaquone. Antimicrob Agents
Chemother 2002, 46:1163–1173.
10. Dressman JB, Reppas C: In vitro-in vivo correlations for lipophilic, poorly
water-soluble drugs. Eur J Pharm Sci 2000, 11(Suppl 2):S73–S80.
11. Danoun S, Baziard-Mouysset G, Stigliani J, Ane-Margail M, Payard M, Leger J,
Canron X, Vial H, Loiseau P, Bories C, Recoche C: Synthesis and
protozoocidal activity of new 1,4-naphthoquinones. Heterocycl Comm
1999, 5:343–348.
12. El Hage S, Ane M, Stigliani J, Marjorie M, Vial H, Baziard-Mouysset G, Payard
M: Synthesis and antimalarial activity of new atovaquone derivatives.
Eur J Med Chem 2009, 44:4778–4782.
13. Hughes L, Lanteri C, O’Neil M, Johnson J, Gribble G, Trumpower B: Design
of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less
susceptible to drug resistance. Mol Biochem Parasitol 2011, 177:12–19.
14. Hughes L, Covian R, Gribble G, Trumpower B: Probing binding
determinants in center P of the cytochrome bc(1) complex using novel
hydroxy-naphthoquinones. Biochim Biophys Acta 2010, 1797:38–43.
15. Ferreira S, da Rocha D, Carneiro J, Santos W, Ferreira V: A new method to
prepare 3-Alkyl-2-hydroxy-1,4-naphthoquinones: synthesis of lapachol
and phthiocol. Synlett 2011, 2011:1551–1554.
16. Trager W, Jensen J: Human malaria parasites in continuous culture.
Science 1976, 193:673–675.
17. Lambros C, Vanderberg J: Synchronization of Plasmodium falciparum
erythrocytic stages in culture. J Parasitol 1979, 65:418–420.
18. Jogdand PS, Singh SK, Christiansen M, Dziegiel MH, Singh S, Theisen M:
Flow cytometric readout based on Mitotracker Red CMXRos staining of
live asexual blood stage malarial parasites reliably assesses antibody
dependent cellular inhibition. Malar J 2012, 11:235.
19. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a
tetrazolium-based semiautomated colorimetric assay: assessment of
chemosensitivity testing. Cancer Res 1987, 47:936–942.
20. Kessl JJ, Meshnick SR, Trumpower BL: Modeling the molecular basis of
atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol
2007, 23:494–501.
21. Kongkathip N, Pradidphol N, Hasitapan K, Grigg R, Kao WC, Hunte C, Fisher
N, Warman AJ, Biagini GA, Kongsaeree P, Chuawong P, Kongkathip B:
Transforming rhinacanthin analogues from potent anticancer agents
into potent antimalarial agents. J Med Chem 2010, 53:1211–1221.
22. Sharma A, Santos I, Gaur P, Ferreira V, Garcia C, Rochab D: Addition of
thiols to o-quinone methide: New 2-hydroxy-3-phenylsulfanylmethyl
[1,4]naphthoquinones and their activity against the human malaria
parasite Plasmodium falciparum (3D7). Eur J Med Chem 2013,
59:48–53.
23. Hudson A, Randall A, Fry M, Ginger C, Hill B, Latter V, McHardy N, Williams R:
Novel anti-malarial hydroxynaphthoquinones with potent broad
spectrum anti-protozoal activity. Parasitology 1985, 90:45–55.
Schuck et al. Malaria Journal 2013, 12:234 Page 5 of 6
http://www.malariajournal.com/content/12/1/234
24. Hammond D, Burchell J, Pudney M: Inhibition of pyrimidine biosynthesis
de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-
1,4-naphthoquinone in vitro. Mol Biochem Parasitol 1985, 14:97–109.
25. Weaver R, Dickins M, Burke M: Cytochrome P450 2C9 is responsible for
hydroxylation of the naphthoquinone antimalarial drug 58C80 in human
liver. Biochem Pharmacol 1993, 46:1183–1197.
26. Kessl JJ, Moskalev NV, Gribble GW, Nasr M, Meshnick SR, Trumpower BL:
Parameters determining the relative efficacy of hydroxy-
naphthoquinone inhibitors of the cytochrome bc1 complex.
Biochim Biophys Acta 2007, 1767:319–326.
doi:10.1186/1475-2875-12-234
Cite this article as: Schuck et al.: Biological evaluation of
hydroxynaphthoquinones as anti-malarials. Malaria Journal 2013 12:234.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schuck et al. Malaria Journal 2013, 12:234 Page 6 of 6
http://www.malariajournal.com/content/12/1/234
